Cipla Expands Consumer Health Portfolio with Ivia Beaute's Acquisition

In a strategic move to bolster its consumer healthcare and wellness offerings, pharmaceutical giantCipla Ltd has announced its acquisition of the cosmetics and personal care distribution and marketing business of Ivia Beaute Pvt Ltd. This acquisition, valued at Rs 130 crore, includes Ivia Beaute's renowned brands Astaberry, Ikin, and Bhimsaini on a global scale.

Cipla to acquire Ivia Beaute's cosmetics, personal care distribution business 

Cipla Health Ltd (CHL), Cipla's wholly-owned subsidiary and consumer healthcare arm, has finalized a Business Transfer Agreement (BTA) for the purchase of Ivia Beaute's distribution and marketing business undertaking. This aligns seamlessly with Cipla's strategic focus on enhancing its presence in the consumer healthcare and wellness sector.

The acquisition, set to be completed within 60 days from the signing of the BTA, signifies Cipla's commitment to diversifying its product portfolio and catering to the evolving needs of consumers. The deal structure involves an initial payment of Rs 130 crore upon closing, with an additional Rs 110 crore contingent upon achieving specified financial milestones over the next three years.

CHL CEO and Whole Time Director, Shivam Puri, expressed enthusiasm about the acquisition, stating,"Integrating Astaberry, Ikin, and Bhimsaini into our portfolio seamlessly complements our existing offerings across key OTC/consumer healthcare categories." Puri emphasized the strategic advantage of expanding Cipla's footprint in Tier 2-6 cities, where there is immense potential for growth in the beauty and personal care sector.

With Astaberry boasting a brand legacy of over 16 years and offering a diverse range of skincare solutions, Cipla aims to leverage its expertise to deliver comprehensive and innovative products to consumers across the globe. The successful completion of the acquisition will pave the way for CHL to initiate the distribution and marketing of these products, further strengthening Cipla's position in the consumer healthcare market.

As Cipla continues to expand its horizons and drive innovation in the healthcare industry, this acquisition underscores its commitment to delivering high-quality products and enhancing the well-being of consumers worldwide. Stay tuned for more updates as Cipla embarks on this exciting new chapter in its journey towards excellence in consumer healthcare.